An Open-Label Safety Study of First-Line Bevacizumab in Combination with Standard Chemotherapy in Chinese Patients with Metastatic Colorectal Cancer Treated in an Expanded Access Program in Taiwan

Kuan Der Lee,Hong Hwa Chen,Hwei-Ming Wang,Chao Jung Tsao,Tzu-Chi Hsu,Chang Fang Chiu,Wu Chou Su,Jeng Yi Wang

An Open-Label Safety Study of First-Line Bevacizumab in Combination with Standard Chemotherapy in Chinese Patients with Metastatic Colorectal Cancer Treated in an Expanded Access Program in Taiwan

2013

Kuan Der Lee
Hong Hwa Chen
Hwei-Ming Wang
Chao Jung Tsao
Tzu-Chi Hsu
Chang Fang Chiu
Wu Chou Su
Jeng Yi Wang

Objective: An increased risk of serious adverse effects related to bevacizumab has been observed in many Western studies for metastatic colorectal cancer. To eval

Keywords:

Urology
Bevacizumab
Pathology
Colorectal cancer
Medicine
Expanded access
Oncology
Adverse effect
Internal medicine
Chemotherapy
open label
increased risk
first line

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations